Home
report store
glioblastoma multiforme gbm epidemiology forecast

glioblastoma-multiforme-gbm-epidemiology-forecast-report

Glioblastoma Multiforme (GBM) - Epidemiology Forecast - 2034

Published Date : 2025

Pages : 188

Region : United States, Japan, EU4 & UK

Summary
TOC Table of Content
LOT
- Sample Request

Glioblastoma Multiforme Epidemiology

Key Highlights

GBM is the most frequently occurring type of primary tumor of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved even though innovative diagnostic strategies and new therapies have been developed.
GBM is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced processes such as speech and emotions. While GBM is highly locally invasive (invading normal brain tissue), it rarely spreads to other organs beyond the brain.
When compared with the adults, Glioblastoma in children is relatively rare.
The total incident cases of GBM in the 7MM were ~35,562 in 2023. Incidents of GBM in Japan are significantly lower than in Europe and the United States.

DelveInsight’s “Glioblastoma Multiforme (GBM) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of GBM, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Geography Covered

The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan

Study Period: 2020–2034

GBM Disease Understanding

GBM Overview

GBM is the most frequently occurring type of primary tumor of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved although innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due to the accumulation of mutations. There is a remarkable development in GBM because it occurs via a complex network of different molecular and genetic aberrations, which leads to significant changes in major signaling pathways. GBMs, as they extensively disperse throughout the parenchyma, making maximal surgical resection unattainable and having a high level of vascularization, are lethal.

Glioma is considered the general term that is used to describe primary brain tumors, and it is also classified according to their presumed cell of origin accordingly.

GBM Diagnosis

The clinical presentation of glioblastoma varies based on factors such as tumor size, location, and the extent of peritumoral edema. The primary diagnostic tool for glioblastoma is contrast-enhanced magnetic resonance imaging (MRI), which is the most commonly used non-invasive technique. For more precise imaging, positron emission tomography (PET) is often recommended, particularly for diagnosing grade III/IV glioblastoma. An innovative approach gaining traction is immunotargeted imaging, which involves using highly specific antibodies that bind to tumor cell surface targets, followed by PET imaging to visualize the tumor. This technique enables real-time monitoring, offering a promising advancement in glioblastoma diagnosis and management.

Further details related to diagnosis will be provided in the report…

GBM Epidemiology

The GBM epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the Total Incident Population of GBM, Gender-specific Incidence Cases of GBM, Type-specific Incidence Cases of GBM, Incident Cases based on Primary Site of GBM, Age-specific Incidence Cases of GBM, Incident Cases Based on Histologic Classification of GBM Tumor, Unmethylation of the MGMT Gene Promoter Cases, BRAF V600E Mutation Cases, and Line-wise Treated Pool of GBM in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

Among the 7MM, the US accounted for approximately 41%, EU4 and the UK for 51%, and Japan for 8% of the total incident cases of GBM in 2023.
In the EU4 and the UK, in 2023, the maximum number of incident cases according to the histological classification was for glioblastoma with 17,549 cases while the lowest incident cases were of giant cell glioblastoma type with 146 cases, which are expected to increase by 2034.
As per the DelveInsight estimates, it has been found that the primary site of GBM included maximum cases at the parietal site, while the minimum number of cases were found in unknown and other sites. This trend is evident across all the 7MM countries for the study period.

GBM Report Insights

Patient Population
Country-wise epidemiology distribution

GBM Report Key Strengths

Eleven Years Forecast
7MM Coverage
GBM Epidemiology Segmentation

GBM Report Assessment

Unmet Needs
Current Diagnostic Practices

FAQs

What are the disease risks, burdens, and unmet needs of GBM? What will be the growth opportunities across the 7MM concerning the patient population with GBM?
What is the historical and forecasted GBM patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand KOLs’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology Methodology

5. GBM Epidemiology Overview at a Glance

5.1. Patient Share (%) Distribution in 2020

5.2. Patient Share (%) Distribution in 2034

6. Disease Background and Overview: GBM

6.1. Introduction

6.2. Classification of GBM

6.3. Glioblastoma Types

6.3.1. Astrocytomas

6.3.2. Ependymomas

6.3.3. Oligodendrogliomas

6.3.4. Mixed gliomas

6.3.5. Optic pathway gliomas

6.4. Symptoms

6.5. Causes

6.6. Pathophysiology

6.6.1. Macroscopic and Histological Features of GBM

6.6.2. Genetic and Molecular Pathogenesis

6.7. Inheritance of GBM

6.7.1. Genetic Variations of GBM

6.7.2. Isocitrate dehydrogenase mutations

6.6.3. O (6)-Methylguanine-DNA methyltransferase promoter methylation

6.6.4. Telomerase reverse transcriptase promoter mutations

6.6.5. Epidermal growth factor receptor aberrations

6.6.6. PTEN alterations

6.6.7. Other novel genetic aberrations

6.8. Molecular Classification

6.8.1. Specific Molecular Biomarkers

6.9. Diagnosis

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Assumptions and Rationale

7.3. Total Incident Cases of GBM in the 7MM

7.4. The US

7.4.1. Total Incident Cases of GBM in the US

7.4.2. Gender-specific Incident Cases of GBM in the US

7.4.3. Type-specific Incident Cases of GBM in the US

7.4.4. Incident Cases based on Primary Site of GBM in the US

7.4.5. Age-specific Incident Cases of GBM in the US

7.4.6. Incident Cases based on Histologic Classification of GBM in the US

7.4.7. Unmethylation of the MGMT Gene Promoter Cases in the US

7.4.8. BRAF V600E Mutation Cases in GBM in the US

7.4.9. Line-wise Treated Pool of GBM in the US

7.5. EU4 and the UK

7.5.1. Total Incident Cases of GBM in EU4 and the UK

7.5.2. Gender-specific Incident Cases of GBM in EU4 and the UK

7.5.3. Type-specific Incident Cases of GBM in EU4 and the UK

7.5.4. Incident Cases based on Primary Site of GBM in EU4 and the UK

7.5.5. Age-specific Incident Cases of GBM in EU4 and the UK

7.5.6. Incident Cases based on Histologic Classification of GBM in EU4 and the UK

7.5.7. Unmethylation of the MGMT Gene Promoter Cases in EU4 and the UK

7.5.8. BRAF V600E Mutation Cases in GBM in EU4 and the UK

7.5.9. Line-wise Treated Pool of GBM in EU4 and the UK

7.6. Japan

7.6.1. Total Incident Cases of GBM in Japan

7.6.2. Gender-specific Incident Cases of GBM in Japan

7.6.3. Type-specific Incident Cases of GBM in Japan

7.6.4. Incident Cases based on Primary Site of GBM in Japan

7.6.5. Age-specific Incident Cases of GBM in Japan

7.6.6. Incident Cases based on Histologic Classification of GBM in Japan

7.6.7. Unmethylation of the MGMT Gene Promoter Cases in Japan

7.6.8. BRAF V600E Mutation Cases in GBM in Japan

7.6.9. Line-wise Treated Pool of GBM in Japan

8. KOL Views

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables:

List of Tables

Table 1: Summary of GBM Epidemiology (2020–2034)

Table 2: Glioma Grading Scale

Table 3: Grading Within Types

Table 4: Total Incident Patient Population of GBM in the 7MM (2020–2034)

Table 5: Total Incident Population of GBM in the US (2020–2034)

Table 6: Gender-specific Incident Cases of GBM in the US (2020–2034)

Table 7: Type-specific Incident Cases of GBM in the US (2020–2034)

Table 8: Incident Cases based on Primary Site of GBM in the US (2020–2034)

Table 9: Age-specific Incident Cases of GBM in the US (2020–2034)

Table 10: Incident Cases Based on Histologic Classification of GBM Tumor in the US (2020–2034)

Table 11: Unmethylation of the MGMT Gene Promoter Cases in the US (2020–2034)

Table 12: BRAF V600E Mutation Cases in the US (2020–2034)

Table 13: Line-wise Treated Pool of GBM in the US (2020–2034)

Table 14: Total Incident Patient Population of GBM in EU4 and the UK (2020–2034)

Table 15: Gender-specific Incident Cases of GBM in EU4 and the UK (2020–2034)

Table 16: Type-specific Incident Cases of GBM in EU4 and the UK (2020–2034)

Table 17: Incident Cases based on Primary Site of GBM in EU4 and the UK (2020–2034)

Table 18: Age-specific Incident Cases of GBM in EU4 and the UK (2020–2034)

Table 19: Incident Cases Based on Histologic Classification of GBM Tumor in EU4 and the UK (2020–2034)

Table 20: Unmethylation of the MGMT Gene Promoter Cases in EU4 and the UK (2020–2034)

Table 21: BRAF V600E Mutation Cases in EU4 and the UK (2020–2034)

Table 22: Line-wise Treated Pool of GBM in EU4 and the UK (2020–2034)

Table 23: Total Incident Population of GBM in Japan (2020–2034)

Table 24: Gender-specific Incident Cases of GBM in Japan (2020–2034)

Table 25: Type-specific Incident Cases of GBM in Japan (2020–2034)

Table 26: Incident Cases based on Primary Site of GBM in the US (2020–2034)

Table 27: Age-specific Incident Cases of GBM in Japan (2020–2034)

Table 28: Incident Cases Based on Histologic Classification of GBM Tumor in Japan (2020–2034)

Table 29: Unmethylation of the MGMT Gene Promoter Cases in Japan (2020–2034)

Table 30: BRAF V600E Mutation Cases in Japan (2020–2034)

Table 31: Line-wise Treated Pool of GBM in Japan (2020–2034)

List of Figures:

List of Figures

Figure 1: Changes from WHO 2016 to 2021 Classification

Figure 2: Generalized Transcription Pathways Related to Glioblastoma Disease

Figure 3: Up-regulated Genetic Pathways in Glioblastoma

Figure 4: Diagnostic Flowchart of Diffuse Gliomas in Adults and Pediatrics

Figure 5: Functioning of MicroRNA as a biomarker in Glioblastoma

Figure 6: Global Heat Map of Brain and CNS Tumor

Figure 7: Total Incident Cases of GBM in the 7MM (2020–2034)

Figure 8: Total Incident Population of GBM in the US (2020–2034)

Figure 9: Gender-specific Incident Cases of GBM in the US (2020–2034)

Figure 10: Type-specific Incident Cases of GBM in the US (2020–2034)

Figure 11: Incident Cases based on Primary Site of GBM in the US (2020–2034)

Figure 12: Age-specific Incident Cases of GBM in the US (2020–2034)

Figure 13: Incident Cases Based on Histologic Classification of GBM Tumor in the US (2020–2034)

Figure 14: Unmethylation of the MGMT Gene Promoter Cases in the US (2020–2034)

Figure 15: BRAF V600E Mutation Cases in the US (2020–2034)

Figure 16: Line-wise Treated Pool of GBM in the US (2020–2034)

Figure 17: Total Incident Cases of GBM in EU4 and the UK (2020–2034)

Figure 18: Gender-specific Incident Cases of GBM in EU4 and the UK (2020–2034)

Figure 19: Type-specific Incident Cases of GBM in EU4 and the UK (2020–2034)

Figure 20: Incident Cases based on Primary Site of GBM in EU4 and the UK (2020–2034)

Figure 21: Age-specific Incident Cases of GBM in EU4 and the UK (2020–2034)

Figure 22: Incident Cases Based on Histologic Classification of GBM Tumor in EU4 and the UK (2020–2034)

Figure 23: Unmethylation of the MGMT Gene Promoter Cases in EU4 and the UK (2020–2034)

Figure 24: BRAF V600E Mutation Cases in EU4 and the UK (2020–2034)

Figure 25: Line-wise Treated Pool of GBM in EU4 and the UK (2020–2034)

Figure 26: Total Incident Population of GBM in Japan (2020–2034)

Figure 27: Gender-specific Incident Cases of GBM in Japan (2020–2034)

Figure 28: Type-specific Incident Cases of GBM in Japan (2020–2034)

Figure 29: Incident Cases based on Primary Site of GBM in Japan (2020–2034)

Figure 30: Age-specific Incident Cases of GBM in Japan (2020–2034)

Figure 31: Incident Cases Based on Histologic Classification of GBM Tumor in Japan (2020–2034)

Figure 32: Unmethylation of the MGMT Gene Promoter Cases in Japan (2020–2034)

Figure 33: BRAF V600E Mutation Cases in Japan (2020–2034)

Figure 34: Line-wise Treated Pool of GBM in Japan (2020–2034)

Related Reports

Glioblastoma multiforme (GBM) - Pipeline Insight, 2025

Glioblastoma multiforme (GBM) Pipeline Insights, 2025 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Glioblastoma multiforme (GBM) market.

Glioblastoma Multiforme (GBM) - Epidemiology Forecast to 2034

DelveInsight's Glioblastoma Multiforme (GBM) - Epidemiology Forecast 2034 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Glioblastoma..

License Type

Offer